Hematologic Oncology

A supplemental new drug application has been submitted to the FDA for the use of ibrutinib as a treatment for patients with marginal zone lymphoma.

Chimeric antigen receptor T-cell therapy targeting CD19 demonstrated a nearly 80% complete remission rate across relapsed/refractory B-cell acute lymphoblastic leukemia patients with multiple levels of disease burden.

Improved understanding of Waldenström's macroglobulinemia and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

The future of imetelstat as a treatment for patients with myelodysplastic syndromes is uncertain following an update on 2 clinical trials.

Almost 90% of patients with previously treated light chain amyloidosis responded to single-agent daratumumab (Darzalex).

Diagnostic criteria and therapeutic strategies for myelodysplastic and myeloproliferative neoplasms continue to evolve as molecular and genetic studies have provided new insights into the diseases.

Clinical experience with lenalidomide (Revlimid) in myelodysplastic syndromes has provided evidence of potential to improve survival and reduce the leukemic progression in patients with 5q-deletion.

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).

The FDA has granted an accelerated approval to blinatumomab (Blincyto) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Treatment with single-agent BCL-2 inhibitor venetoclax demonstrated an overall response rate of 19% with a tolerable safety profile in patients who were unfit for intensive chemotherapy for those with relapsed/refractory acute myeloid leukemia.

The FDA has granted pracinostat a breakthrough therapy designation for use in combination with azacitidine as a treatment for patients with newly diagnosed acute myeloid leukemia who are aged ≥75 years or ineligible for intensive chemotherapy.

Brentuximab vedotin (Adcetris) significantly improved the rate of responses lasting at least 4 months in patients with CD-30­–positive cutaneous T-cell lymphoma, meeting the primary endpoint of the phase III ALCANZA trial.

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.